Table 1 Demographic, clinical, serological and capillaroscopic data of the eSSc and UCTD patients
Feature | Early SSc | UCTD | P |
|---|---|---|---|
n = 31 | n = 35 | ||
Sex: F/M (n) | 29/2 | 34/1 | ns |
Age; years (median; range) | 41 (17–64) | 40 (18–73) | ns |
RaP duration; years (median; range) | 3 (1–24) | 4 (0.5-30) | ns |
Puffy fingers (n;%) | 3 (9.6) | 0 (0) | ns |
History of arthritis (n;%) | 0 (0) | 4 (11.4) | 0.052 |
ESR >20 mm/h (n;%) | 5 (16.1) | 3 (8.5) | ns |
Gammaglobulins > 1.5 g/dl (n;%) | 2 (6.4) | 2 (5.7) | ns |
C3 < 80 mg/dl or C4 < 15 mg/dl (n;%) | 2 (6.4) | 3 (8.5) | ns |
DLCO < 80% of predicted (n;%) | 7 (22.5) | 5/20 (25.0)* | ns |
E/A ratio < 1** (n;%) | 2 (6.4) | 1 (2.8) | ns |
ANA + (n;%) | 30 (96.7) | 35 (100) | ns |
SSc-marker antibodies + (n;%) | 27 (87.0) | 0 (0) | - |
ACA + (n;%) | 20 (64.5) | 0 (0) | - |
Anti-Scl-70 + (n;%) | 6 (19.3) | 0 (0) | - |
ESSG-AI > 3 (n;%) | 0 (0) | - | - |
NCM SSc pattern (n;%) | 22 (70.9) | 0 (0) | - |
Calcium channel blockers (n;%) | 31 (100) | 35 (100) | ns |